Roberto Grimaldi
Plus aucun poste en cours
Profil
Roberto Grimaldi worked as an Executive Vice President at Crucell Biologics, Inc. and as a Principal at Seqirus Vaccines Ltd., Sandoz Corp., and Mucosis BV.
He obtained an undergraduate degree from the University of Pavia.
Anciens postes connus de Roberto Grimaldi
| Sociétés | Poste | Fin |
|---|---|---|
Sandoz Corp.
 Sandoz Corp. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Sandoz Corp. develops, produces, and markets medicines. | Corporate Officer/Principal | - |
Crucell Biologics, Inc.
 Crucell Biologics, Inc. Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Crucell Biologics, Inc. is a company that manufactures and supplies biopharmaceutical products. The company is based in Miami, FL. | Corporate Officer/Principal | - |
Seqirus Vaccines Ltd.
 Seqirus Vaccines Ltd. BiotechnologyHealth Technology Seqirus Vaccines Ltd. manufactures vaccines. The company is headquartered in Maidenhead, the United Kingdom. | Corporate Officer/Principal | - |
Mucosis BV
 Mucosis BV Miscellaneous Commercial ServicesCommercial Services Mucosis BV develops mucosal vaccines for infectious diseases. Its product is SynGEM, an intranasal vaccine to prevent respiratory syncytial virus infection. Its vaccines are based on the patented and validated Mimopath technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in the proof-of-concept animal and human studies of our FluGEM vaccine candidate. The company was founded by Cornelis Leenhouts in 2007 and is headquartered in Groningen, the Netherlands. | Directeur Technique/Scientifique/R&D | - |
Formation de Roberto Grimaldi
| University of Pavia | Undergraduate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Mucosis BV
Mucosis BV Miscellaneous Commercial ServicesCommercial Services Mucosis BV develops mucosal vaccines for infectious diseases. Its product is SynGEM, an intranasal vaccine to prevent respiratory syncytial virus infection. Its vaccines are based on the patented and validated Mimopath technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in the proof-of-concept animal and human studies of our FluGEM vaccine candidate. The company was founded by Cornelis Leenhouts in 2007 and is headquartered in Groningen, the Netherlands. | Commercial Services |
Crucell Biologics, Inc.
Crucell Biologics, Inc. Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Crucell Biologics, Inc. is a company that manufactures and supplies biopharmaceutical products. The company is based in Miami, FL. | Health Technology |
Seqirus Vaccines Ltd.
Seqirus Vaccines Ltd. BiotechnologyHealth Technology Seqirus Vaccines Ltd. manufactures vaccines. The company is headquartered in Maidenhead, the United Kingdom. | Health Technology |
Sandoz Corp.
Sandoz Corp. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Sandoz Corp. develops, produces, and markets medicines. | Health Technology |
